PAPER Maze I, Covington HE, Dietz DM, LaPlant Q, Renthal W, Russo SJ, Mechanic M, Mouzon E, Neve RL, Haggarty SJ, Ren Y, Sampath SC, Hurd YL, Greengard P, Tarakhovsky A, Schaefer A, Nestler EJ
SEARCH RESULTS
331007 RESULTS
James Cooper on CTAD: AD Treatment Might Not Lower Healthcare Costs
COMMENT The results of a model depend, of course, on the assumptions used for the variables in the model. For example, Dr. Wimo and colleagues concluded, in another model, that treatment of dementia with an ACEI was cost neutral. A truly successful disease-modify
Kenneth Augustyn
SRI InternationalAnn Arbor, United States
Clinical Trials on Alzheimer's Disease 2012
CONFERENCE COVERAGE SERIES CTAD: Turning the Ship Around Toward Early Trials CTAD: New Data on Sola, Bapi, Spark Theragnostics Debate CTAD: Regulatory Science Gains Prominence in AD Research CTAD: Adaptive Antibody Trial to Try Bayesian Statistics CTAD: ApoE Carriers Sought for Tri
Lotta Agholme
Cellectricon ABGothenburg, Sweden
CTAD: AD Treatment Might Not Lower Healthcare Costs
CONFERENCE COVERAGE 2012-11-21 Conference Coverage Stakeholders in the Alzheimer’s disease field often cite the tremendous burden the disease puts on the healthcare system—estimated at $600 billion annually worldwide (see World Alzheimer Report 2010 and ARF related news story)—as a com
Boxing: Study of Human Model for CTE Enters Second Round
CONFERENCE COVERAGE 2012-11-21 Conference Coverage Viewed through a scientist’s lens, professional boxing is a series of scheduled, measurable head traumas. In other words, it is a human model for chronic traumatic encephalopathy (CTE). Seen this way, the sport offers a unique opportun
Déjà Vu? AD Patients Again Look Worse on γ-Secretase Inhibitor
RESEARCH NEWS 2012-11-21 Research News In a Phase 2 trial of Bristol-Myers Squibb’s oral γ-secretase inhibitor avagacestat, AD patients who took high doses suffered more adverse effects and appeared to fare worse cognitively than those on placebo. Christopher van Dyck of Yale Uni
SfN: Epigenetic Changes in Alzheimer’s and Cognitive Decline
CONFERENCE COVERAGE 2012-11-21 Conference Coverage Franklin’s genius notwithstanding, death and taxes are not the only things that are certain. It’s pretty clear you can’t evade your genetics, either. But what about epigenetics? While tweaking the tax code might improve your fortune, c
PAPER Bertoux M, Volle E, Funkiewiez A, de Souza LC, Leclercq D, Dubois B
Social Cognition and Emotional Assessment (SEA) is a marker of medial and orbital frontal functions: a voxel-based morphometry study in behavioral variant of frontotemporal degeneration.
J Int Neuropsychol Soc. 2012 Nov;18(6):972-85. PubMed: 23158228PAPER Barandiaran M, Estanga A, Moreno F, Indakoetxea B, Alzualde A, Balluerka N, Martí Massó JF, de Munain AL
Neuropsychological features of asymptomatic c.709-1G> A progranulin mutation carriers.
J Int Neuropsychol Soc. 2012 Nov;18(6):1086-90. PubMed: 23158232PAPER van Blitterswijk M, Dejesus-Hernandez M, Rademakers R
How do C9ORF72 repeat expansions cause amyotrophic lateral sclerosis and frontotemporal dementia: can we learn from other noncoding repeat expansion disorders?
Curr Opin Neurol. 2012 Dec;25(6):689-700. PubMed: 23160421PAPER Goodwin J, Nath S, Engelborghs Y, Pountney DL
Raised calcium and oxidative stress cooperatively promote alpha-synuclein aggregate formation.
Neurochem Int. 2012 Nov 15; PubMed: 23159813PAPER Narayanan C, Weinstock DS, Wu KP, Baum J, Levy RM
Investigation of the Polymeric Properties of α-Synuclein and Comparison with NMR Experiments: A Replica Exchange Molecular Dynamics Study.
J Chem Theory Comput. 2012 Oct 9;8(10):3929-3942. PubMed: 23162382PAPER Thakur P, Nehru B
Anti-inflammatory properties rather than anti-oxidant capability is the major mechanism of neuroprotection by sodium salicylate in a chronic rotenone model of Parkinson's disease.
Neuroscience. 2013 Feb 12;231:420-31. PubMed: 23159314Current Filters
No filters selected